Target family: Metabotropic glutamate receptors (type: gpcr)
Target: mGlu<sub>7</sub> receptor

Ligand: (1S,3R)-ACPD (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 3.1 pKi
Reference (Journal): Binding of [3H](2S,1'S,2'S)-2-(9-xanthylmethyl)-2-(2'-carboxycyclopropyl) glycine ([3H]LY341495) to cell membranes expressing recombinant human group III metabotropic glutamate receptor subtypes.
Published in: Naunyn Schmiedebergs Arch Pharmacol

Ligand: (1S,3R)-ACPD (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 3 pKi
Reference (Journal): Binding of [3H](2S,1'S,2'S)-2-(9-xanthylmethyl)-2-(2'-carboxycyclopropyl) glycine ([3H]LY341495) to cell membranes expressing recombinant human group III metabotropic glutamate receptor subtypes.
Published in: Naunyn Schmiedebergs Arch Pharmacol

Ligand: ADX71743 (Synthetic organic)
Interaction type: Allosteric modulator
Action: Negative
Ligand approved: no
Median affinity: 7.1 pIC50
Reference (Journal): ADX71743, a potent and selective negative allosteric modulator of metabotropic glutamate receptor 7: in vitro and in vivo characterization.
Published in: J Pharmacol Exp Ther

Ligand: ADX71743 (Synthetic organic)
Interaction type: Allosteric modulator
Action: Negative
Ligand approved: no
Primary target: no
Median affinity: 7.199999809265137 pIC50
Reference (Journal): ADX71743, a potent and selective negative allosteric modulator of metabotropic glutamate receptor 7: in vitro and in vivo characterization.
Published in: J Pharmacol Exp Ther

Ligand: α-methylserine-O-phosphate (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 4.4 pKi
Reference (Journal): Binding of [3H](2S,1'S,2'S)-2-(9-xanthylmethyl)-2-(2'-carboxycyclopropyl) glycine ([3H]LY341495) to cell membranes expressing recombinant human group III metabotropic glutamate receptor subtypes.
Published in: Naunyn Schmiedebergs Arch Pharmacol

Ligand: AMN082 (Synthetic organic)
Interaction type: Allosteric modulator
Action: Positive
Ligand approved: no
Median affinity:  pEC50
Reference (Journal): A selective metabotropic glutamate receptor 7 agonist: activation of receptor signaling via an allosteric site modulates stress parameters in vivo.
Published in: Proc Natl Acad Sci USA

Ligand: DCG-IV (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 4.7 pKi
Reference (Journal): Binding of [3H](2S,1'S,2'S)-2-(9-xanthylmethyl)-2-(2'-carboxycyclopropyl) glycine ([3H]LY341495) to cell membranes expressing recombinant human group III metabotropic glutamate receptor subtypes.
Published in: Naunyn Schmiedebergs Arch Pharmacol

Ligand: (R,S)-4-PPG (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 3.7 pIC50
Reference (Journal): (R,S)-4-phosphonophenylglycine, a potent and selective group III metabotropic glutamate receptor agonist is anticonvulsive and neuroprotective<i>in vivo</i>.
Published in: J Pharmacol Exp Ther

Ligand: (R,S)-4-PPG (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 3.7 pIC50
Reference (Journal): (+)-4-phosphonophenylglycine (PPG) a new group III selective metabotropic glutamate receptor agonist.
Published in: Bioorg Med Chem Lett

Ligand: L-AP4 (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 3.7 pKi
Reference (Journal): Binding of [3H](2S,1'S,2'S)-2-(9-xanthylmethyl)-2-(2'-carboxycyclopropyl) glycine ([3H]LY341495) to cell membranes expressing recombinant human group III metabotropic glutamate receptor subtypes.
Published in: Naunyn Schmiedebergs Arch Pharmacol

Ligand: L-AP4 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 3.8 pEC50
Reference (Journal): Group III human metabotropic glutamate receptors 4, 7 and 8: molecular cloning, functional expression, and comparison of pharmacological properties in RGT cells.
Published in: Brain Res Mol Brain Res

Ligand: L-CCG-I (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 4.3 pKi
Reference (Journal): Binding of [3H](2S,1'S,2'S)-2-(9-xanthylmethyl)-2-(2'-carboxycyclopropyl) glycine ([3H]LY341495) to cell membranes expressing recombinant human group III metabotropic glutamate receptor subtypes.
Published in: Naunyn Schmiedebergs Arch Pharmacol

Ligand: L-glutamic acid (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 3.1 pKi
Reference (Journal): Binding of [3H](2S,1'S,2'S)-2-(9-xanthylmethyl)-2-(2'-carboxycyclopropyl) glycine ([3H]LY341495) to cell membranes expressing recombinant human group III metabotropic glutamate receptor subtypes.
Published in: Naunyn Schmiedebergs Arch Pharmacol

Ligand: L-glutamic acid (Metabolite)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 3 pEC50
Reference (Journal): New perspectives for the development of selective metabotropic glutamate receptor ligands.
Published in: Eur J Pharmacol

Ligand: L-serine-O-phosphate (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 4.4 pKi
Reference (Journal): Binding of [3H](2S,1'S,2'S)-2-(9-xanthylmethyl)-2-(2'-carboxycyclopropyl) glycine ([3H]LY341495) to cell membranes expressing recombinant human group III metabotropic glutamate receptor subtypes.
Published in: Naunyn Schmiedebergs Arch Pharmacol

Ligand: L-serine-O-phosphate (Metabolite)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 4.5 pEC50
Reference (Journal): Group III human metabotropic glutamate receptors 4, 7 and 8: molecular cloning, functional expression, and comparison of pharmacological properties in RGT cells.
Published in: Brain Res Mol Brain Res

Ligand: LSP1-2111 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 4.28 pEC50
Reference (Journal): Electrophysiological and behavioral evidence that modulation of metabotropic glutamate receptor 4 with a new agonist reverses experimental parkinsonism.
Published in: FASEB J

Ligand: LSP4-2022 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 4.940000057220459 pEC50
Reference (Journal): A novel selective metabotropic glutamate receptor 4 agonist reveals new possibilities for developing subtype selective ligands with therapeutic potential.
Published in: FASEB J

Ligand: LY341495 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 6.7 pKi
Reference (Journal): Binding of [3H](2S,1'S,2'S)-2-(9-xanthylmethyl)-2-(2'-carboxycyclopropyl) glycine ([3H]LY341495) to cell membranes expressing recombinant human group III metabotropic glutamate receptor subtypes.
Published in: Naunyn Schmiedebergs Arch Pharmacol

Ligand: MAP4 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 3.8 pKi
Reference (Journal): Binding of [3H](2S,1'S,2'S)-2-(9-xanthylmethyl)-2-(2'-carboxycyclopropyl) glycine ([3H]LY341495) to cell membranes expressing recombinant human group III metabotropic glutamate receptor subtypes.
Published in: Naunyn Schmiedebergs Arch Pharmacol

Ligand: MCCG (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 3.2 pKi
Reference (Journal): Binding of [3H](2S,1'S,2'S)-2-(9-xanthylmethyl)-2-(2'-carboxycyclopropyl) glycine ([3H]LY341495) to cell membranes expressing recombinant human group III metabotropic glutamate receptor subtypes.
Published in: Naunyn Schmiedebergs Arch Pharmacol

Ligand: (+)-MCPG (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 3.2 pKi
Reference (Journal): Binding of [3H](2S,1'S,2'S)-2-(9-xanthylmethyl)-2-(2'-carboxycyclopropyl) glycine ([3H]LY341495) to cell membranes expressing recombinant human group III metabotropic glutamate receptor subtypes.
Published in: Naunyn Schmiedebergs Arch Pharmacol

Ligand: MDIP (Synthetic organic)
Interaction type: Allosteric modulator
Action: Negative
Ligand approved: no
Median affinity: 7.6 pIC50
Reference (Journal): In vitro pharmacological characterization of novel isoxazolopyridone derivatives as allosteric metabotropic glutamate receptor 7 antagonists.
Published in: J Pharmacol Exp Ther

Ligand: MMPIP (Synthetic organic)
Interaction type: Allosteric modulator
Action: Negative
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): In vitro pharmacological characterization of novel isoxazolopyridone derivatives as allosteric metabotropic glutamate receptor 7 antagonists.
Published in: J Pharmacol Exp Ther

Ligand: MMPIP (Synthetic organic)
Interaction type: Allosteric modulator
Action: Negative
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): Context-dependent pharmacology exhibited by negative allosteric modulators of metabotropic glutamate receptor 7.
Published in: Mol Pharmacol

Ligand: MPPG (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 3.8 pKi
Reference (Journal): Binding of [3H](2S,1'S,2'S)-2-(9-xanthylmethyl)-2-(2'-carboxycyclopropyl) glycine ([3H]LY341495) to cell membranes expressing recombinant human group III metabotropic glutamate receptor subtypes.
Published in: Naunyn Schmiedebergs Arch Pharmacol

Ligand: MSOPPE (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 3.6 pKi
Reference (Journal): Binding of [3H](2S,1'S,2'S)-2-(9-xanthylmethyl)-2-(2'-carboxycyclopropyl) glycine ([3H]LY341495) to cell membranes expressing recombinant human group III metabotropic glutamate receptor subtypes.
Published in: Naunyn Schmiedebergs Arch Pharmacol

Ligand: PPG (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 3.7 pKi
Reference (Journal): Binding of [3H](2S,1'S,2'S)-2-(9-xanthylmethyl)-2-(2'-carboxycyclopropyl) glycine ([3H]LY341495) to cell membranes expressing recombinant human group III metabotropic glutamate receptor subtypes.
Published in: Naunyn Schmiedebergs Arch Pharmacol

Ligand: [3H]LY341495 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 7.1 pKd
Reference (Journal): Binding of [3H](2S,1'S,2'S)-2-(9-xanthylmethyl)-2-(2'-carboxycyclopropyl) glycine ([3H]LY341495) to cell membranes expressing recombinant human group III metabotropic glutamate receptor subtypes.
Published in: Naunyn Schmiedebergs Arch Pharmacol

Ligand: VU6010608 (Synthetic organic)
Interaction type: Allosteric modulator
Action: Negative
Ligand approved: no
Primary target: yes
Median affinity: 6.119999885559082 pIC50
Reference (Journal): VU6010608, a Novel mGlu<sub>7</sub> NAM from a Series of <i>N</i>-(2-(1<i>H</i>-1,2,4-Triazol-1-yl)-5-(trifluoromethoxy)phenyl)benzamides.
Published in: ACS Med Chem Lett

Ligand: VU6012962 (Synthetic organic)
Interaction type: Allosteric modulator
Action: Negative
Ligand approved: no
Primary target: no
Median affinity: 6.460000038146973 pIC50
Reference (Journal): Discovery of an Orally Bioavailable and Central Nervous System (CNS) Penetrant mGlu<sub>7</sub> Negative Allosteric Modulator (NAM) in Vivo Tool Compound: N-(2-(1 H-1,2,4-triazol-1-yl)-5-(trifluoromethoxy)phenyl)-4-(cyclopropylmethoxy)-3-methoxybenzamide (VU6012962).
Published in: J Med Chem

Ligand: XAP044 (Synthetic organic)
Interaction type: Allosteric modulator
Action: Negative
Ligand approved: no
Primary target: yes
Median affinity: 5.550000190734863 pIC50
Reference (Journal): Blocking metabotropic glutamate receptor subtype 7 (mGlu7) via the Venus flytrap domain (VFTD) inhibits amygdala plasticity, stress, and anxiety-related behavior.
Published in: J Biol Chem